Addex Pharmaceuticals Ltd. (ADXN.SW)
-Swiss 3.74 
0.20(5.08%) 11:30AM EDT
| Prev Close: | 3.94 |
|---|
| Open: | 3.95 |
|---|
| Bid: | 3.74 |
|---|
| Ask: | 3.84 |
|---|
| 1y Target Est: | 14.50 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.71 - 3.95 |
|---|
| 52wk Range: | 3.33 - 12.50 |
|---|
| Volume: | 31,611 |
|---|
| Avg Vol (3m): | 27,787 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CHF.
Headlines
- Addex Therapeutics – Worth a Look After a 61% Drop in Share Price?Zacks Small Cap Research(Fri, Jun 7)
- Swiss stocks - Factors to watch on June 3at Reuters(Mon, Jun 3)
- Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps DownThomson Reuters ONE(Fri, May 31)
- Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for ShareholdersThomson Reuters ONE(Tue, May 28)
- Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441Thomson Reuters ONE(Tue, May 21)
- Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET StudyThomson Reuters ONE(Wed, May 1)
- Addex Announces CFO, Tim Dyer, to Transition to External Consulting RoleThomson Reuters ONE(Tue, Apr 30)
- Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol DependenceThomson Reuters ONE(Tue, Apr 30)
- Addex Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441Thomson Reuters ONE(Wed, Apr 24)
- Addex Announces Issuance of a Broad European Composition of Matter Patent for DipraglurantThomson Reuters ONE(Mon, Apr 22)
- Swiss stocks - Factors to watch on April 18at Reuters(Thu, Apr 18)
- Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)Thomson Reuters ONE(Thu, Apr 18)
- Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)Thomson Reuters ONE(Thu, Mar 21)
- Addex Shareholders Approve All Board Proposals at Annual General MeetingThomson Reuters ONE(Wed, Mar 20)
- Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's ResearchThomson Reuters ONE(Tue, Mar 19)
Reports
- No Reports available for ADXN.SW at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-11)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forADXN.SW.